亚太地区抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术(可裂解接头和不可裂解接头)、应用(血液癌、乳腺癌、卵巢癌、尿路上皮癌等)和分销渠道(医院药房、零售药店和网上药店)

BMIRE00029769 | Pages: 101 | Pharmaceuticals | Mar 2024 | Type: Regional | Status: Published
2022年亚太地区抗体药物偶联物市场价值为15.3283亿美元,预计到2030年将达到69.7103亿美元;预计 2022 年至 2030 年复合年增长率为 20.8%。

同意管理中人工智能的需求不断增长,推动亚太抗体药物偶联物市场

癌症发病率上升主要导致对创新癌症治疗的需求不断增长。根据全球癌症观察站 (GLOBOCAN) 2020 年发布的估计,全球有 1930 万癌症病例。中国和印度是癌症病例最多的国家之一。 GLOBOCAN 还估计,到 2040 年,印度的癌症病例将约为 208 万,比 2020 年增长 57.5%。同样,根据世界卫生组织 (WHO) 2022 年 2 月发布的数据,约有 1000 万人患有癌症。死于癌症。最常见的癌症类型是肺癌、乳腺癌、结肠癌和直肠癌、前列腺癌和乳腺癌。癌症发病率的上升引起了全世界的关注。以下是 2020 年全球报告的常见癌症病例列表。

表 1. 2020 年全球新癌症病例

Sr.编号 癌症类型 病例数(百万)

1 胃癌 1.09

2 皮肤(非黑色素瘤)1.2

3 前列腺 1.41

4 结肠直肠 1.93

5 肺 2.21

6 乳房 2.26

癌症现在是一种生活方式疾病,常见于饮食习惯不健康和缺乏运动的人群。此外,饮酒和吸烟也会增加患癌症的风险。低收入和中等收入国家的慢性传染病可进一步加剧癌症危险因素。根据世界卫生组织2022年2月公布的数据,2018年诊断的人中近18%患有人乳头瘤病毒(HPV)、幽门螺杆菌、乙型肝炎病毒、丙型肝炎病毒和EB病毒等慢性传染病。 ADC 的良好结果预计将加速其作为有效癌症治疗方法的需求并推动市场增长。

亚太地区抗体药物偶联物市场概览

亚太地区抗体药物偶联物 (ADC) 市场分为中国、日本、印度、韩国、澳大利亚和亚太其他地区。 ADC 市场的增长广泛受到公司合作、癌症发病率上升和临床试验增加的推动。

亚太国家参与开发ADC的领先公司已有管道产品在完成临床试验后即将推向市场。 2023年6月,荣昌生物与信达生物签署协议,进入临床试验并提供达伯舒(信迪利单抗注射液)与新型间皮素(MSLN)靶向抗体药物偶联物(ADC)RC88的联合疗法,或达伯舒 (TYVYT) 与 RC108,一种新型 c-Met 靶向 ADC。这些据称是治疗实体瘤的新疗法。根据协议,荣昌生物将对达伯舒进行1/2a期临床研究,以评估其抗肿瘤活性和安全性。该公司还有 Distamab vedotin (RC48) + PD1 组合正在研发中。该组合针对不同的癌症适应症分两个阶段进行评估,第一个组合处于 III 期,评估用于治疗尿路上皮癌,第二个组合处于 II 期,评估用于治疗肌肉浸润性膀胱癌和胃癌。

此外,日本公司正在推出突破性产品,预计将主导 ADC 市场。 2021 年 6 月,第一三共株式会社和阿斯利康公司推出了 Enhertu,这是一类新型 ADC,专为治疗 HER2 低乳腺癌患者而开发。第一三共株式会社报告称,按美国和欧洲销售额计算,2023 年第一季度销售额同比增长 156.6%。公司销售额的如此巨大增长极大地扩大了该国 ADC 市场规模,预计未来几年将呈指数级增长。

亚太地区抗体药物偶联物市场收入及预测至 2030 年(百万美元)

亚太地区抗体药物偶联物市场细分

亚太地区抗体药物偶联物市场已细分基于技术、应用、分销渠道和国家。

根据技术,亚太地区抗体药物偶联物市场抗体药物偶联物市场分为可裂解接头和不可裂解接头。到2022年,可裂解接头细分市场将占据更大份额。

根据应用,亚太地区抗体药物偶联物市场抗体药物偶联物市场分为血癌、乳腺癌、卵巢癌、尿路上皮癌等。乳腺癌细分市场在 2022 年占据最大份额。

根据分销渠道,亚太地区抗体药物偶联物市场抗体药物偶联物市场分为医院药房、零售药房和在线药房。 2022 年,医院药房市场占据最大份额。

按国家/地区划分,亚太地区抗体药物偶联物市场分为澳大利亚、中国、印度、日本、韩国和亚太其他地区。 2022 年,日本在亚太地区抗体药物偶联物市场占据主导地位。

辉瑞公司、罗氏公司、葛兰素史克公司、吉利德科学公司、阿斯利康公司、安斯泰来制药公司、荣昌制药有限公司和武田制药有限公司是亚太地区抗体药物偶联物市场的一些领先公司。

Table of Content

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Market Attractiveness

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Antibody Drug Conjugates Market - Key Industry Dynamics

4.1 Key Market Drivers:

4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates

4.1.2 Rising Incidences of Cancer Cases

4.1.3 Increasing FDA Approvals for ADCs

4.2 Market Restraints

4.2.1 High Cost of ADCs Development and Commercialization

4.3 Market Opportunities

4.3.1 Increasing Investments to Develop ADCs

4.4 Market Trends

4.4.1 Escalating Pipeline of ADCs

4.5 Impact Analysis:

5. Antibody Drug Conjugates Market - Asia Pacific Market Analysis

5.1 Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

6. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

6.1 Overview

6.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)

6.3 Cleavable Linker

6.3.1 Overview

6.3.2 Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

6.4 Non-cleavable Linker

6.4.1 Overview

6.4.2 Non-cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

7.1 Overview

7.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)

7.3 Blood Cancer

7.3.1 Overview

7.3.2 Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Breast Cancer

7.4.1 Overview

7.4.2 Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Ovarian Cancer

7.5.1 Overview

7.5.2 Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7.6 Urothelial Cancer

7.6.1 Overview

7.6.2 Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7.7 Others

7.7.1 Overview

7.7.2 Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview

8.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)

8.3 Hospital Pharmacies

8.3.1 Overview

8.3.2 Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Retail Pharmacies

8.4.1 Overview

8.4.2 Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8.5 Online Pharmacies

8.5.1 Overview

8.5.2 Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Antibody Drug Conjugates Market - Country Analysis

9.1 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030

9.1.1 Overview

9.1.2 Asia Pacific Antibody Drug Conjugates Market Breakdown, by key Country - Revenue (2022) (US$ Million)

9.1.3 Asia Pacific: Antibody Drug Conjugates Market, by Country

9.1.3.1 China

9.1.3.1.1 Overview

9.1.3.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.1.3 China: Antibody Drug Conjugates Market, by Technology

9.1.3.1.4 China: Antibody Drug Conjugates Market, by Application

9.1.3.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.2 Japan

9.1.3.2.1 Overview

9.1.3.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.2.3 Japan: Antibody Drug Conjugates Market, by Technology

9.1.3.2.4 Japan: Antibody Drug Conjugates Market, by Application

9.1.3.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.3 India

9.1.3.3.1 Overview

9.1.3.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.3.3 India: Antibody Drug Conjugates Market, by Technology

9.1.3.3.4 India: Antibody Drug Conjugates Market, by Application

9.1.3.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.4 South Korea

9.1.3.4.1 Overview

9.1.3.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.4.3 South Korea: Antibody Drug Conjugates Market, by Technology

9.1.3.4.4 South Korea: Antibody Drug Conjugates Market, by Application

9.1.3.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.5 Australia

9.1.3.5.1 Overview

9.1.3.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.5.3 Australia: Antibody Drug Conjugates Market, by Technology

9.1.3.5.4 Australia: Antibody Drug Conjugates Market, by Application

9.1.3.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.6 Rest of Asia Pacific

9.1.3.6.1 Overview

9.1.3.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology

9.1.3.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application

9.1.3.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel

10. Asia Pacific Antibody Drug Conjugates Market-Industry Landscape

10.1 Overview

10.2 Organic Growth Strategies

10.2.1 Overview

10.3 Inorganic Growth Strategies

10.3.1 Overview

10.4 Companies' Manufacturing Capacities and Capabilities

11. Company Profiles

11.1 Pfizer Inc

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Hoffmann-La Roche Ltd

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 GSK Plc

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 Gilead Sciences Inc

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 AstraZeneca Plc

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Astellas Pharma Inc

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 RemeGen Co Ltd

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 Takeda Pharmaceutical Co Ltd

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

12. Appendix

12.1 About Us

12.2 Glossary of Terms

 

 

List of Tables

Table 1. Asia Pacific Antibody Drug Conjugates Market Segmentation

Table 2. New Cancer Cases Worldwide, in 2020

Table 3. List of FDA-Approved ADCs

Table 4. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 5. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 6. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 7. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 8. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 9. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 10. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 11. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 12. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 13. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 14. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 15. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 16. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 17. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 18. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 19. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 20. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 21. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 22. Recent Organic Growth Strategies in Antibody Drug Conjugates Market

Table 23. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market

Table 24. Glossary of Terms, Antibody Drug Conjugates Market

List of Figures

Figure 1. Asia Pacific Antibody Drug Conjugates Market Segmentation, By Country

Figure 2. Key Insights

Figure 3. Asia Pacific Antibody Drug Conjugates Market - Key Industry Dynamics

Figure 4. Impact Analysis of Drivers and Restraints

Figure 5. Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

Figure 6. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)

Figure 7. Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Non-Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)

Figure 10. Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 11. Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 15. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)

Figure 16. Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 19. Asia Pacific Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)

Figure 20. Asia Pacific: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)

Figure 21. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 22. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 23. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 24. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 25. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 26. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

1. Pfizer Inc
2. Hoffmann-La Roche Ltd
3. GSK Plc
4. Gilead Sciences Inc
5. AstraZeneca Plc
6. Astellas Pharma Inc
7. RemeGen Co Ltd
8. Takeda Pharmaceutical Co Ltd

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific antibody drug conjugates market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440